Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-420 in Transfusional Iron Overload
NCT04741542Phase 1Terminated
- Sponsor
- UT Health San Antonio
- Start
- Mar 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of petadeferitrin in Transfusional Iron Overload (TIO) (4 arms), sponsored by UT Health San Antonio. Primary endpoints: Number of adverse events at 28 Days and Completion at original dose at 28 Days. Started Mar 2021; status: terminated.
02
Drugs
petadeferitrin
03
Conditions
Transfusional Iron Overload (TIO)
Beyond the preview
Go deeper on NCT04741542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04741542.